In clinical trials of 118 children or adolescents 3 to 16 years of age, 6% discontinued therapy due to adverse events.
Kliinilises uuringus katkestas kõrvaltoimete tõttu ravi 6% 118- st 3 kuni 16 aastastest lastest ja noorukitest.